How to Treat RSV in Adults: What Actually Works

There is no FDA-approved antiviral that cures RSV in adults, so treatment remains overwhelmingly supportive: fluids, supplemental oxygen when needed, and managing complications as they arise. That answer frustrates a lot of people, especially given that RSV hospitalizes hundreds of thousands of older adults each year and carries mortality risk comparable to influenza. But the landscape is not as bleak as “just ride it out” implies. Ribavirin sees real use in transplant recipients, several promising antivirals are working through clinical trials, and knowing how to handle the complications RSV triggers can make a meaningful difference in outcomes.

Why RSV in Adults Gets Taken Less Seriously Than It Should

RSV has long been framed as a childhood illness, but the burden in adults is enormous. Among U.S. adults aged 60 and older, an estimated 4 million RSV cases occur annually, producing roughly $6.6 billion in combined direct medical and indirect costs. Hospitalized cases account for only about 4 percent of total infections, yet they drive 94 percent of the direct medical spending.¹ A large study comparing RSV with influenza and SARS-CoV-2 found that RSV patients were the oldest group on average (around 75 years), stayed in the hospital longer than influenza patients, and faced higher odds of ICU admission and mechanical ventilation than either influenza A or B.²

The problem is recognition. RSV symptoms in adults look like a bad cold or flu: congestion, cough, low-grade fever, fatigue. Neither clinical appearance nor basic lab work reliably distinguishes RSV from influenza or COVID-19.² That means many adult RSV infections go undiagnosed. Without a positive test, you never get targeted thinking about RSV-specific complications or monitoring, and treatment defaults to generic respiratory illness management.

Who Faces the Highest Risk

If you are otherwise healthy and middle-aged, RSV is usually an unpleasant week of coughing and congestion that resolves on its own. The danger concentrates in specific groups. Older adults with underlying heart or lung disease and people with weakened immune systems face the highest risk of RSV progressing to pneumonia or death.³ A large Mexican surveillance study found that more than half of RSV patients aged 50 and older had multiple chronic conditions, and the fatality rate in that group was about 13 percent.⁴

The biological reasons are well-mapped. As the immune system ages, its ability to mount a coordinated response to RSV weakens. On top of that, chronic conditions like COPD and heart failure create damaged airway linings, ongoing inflammation, and reduced reserve capacity. RSV exploits all of these vulnerabilities, causing epithelial damage, worsening existing inflammation, and in some cases directly injuring heart muscle.⁵ RSV has also been found in roughly 12.5 percent of hospitalized older adults initially evaluated for flu-like illness, and it can trigger cardiovascular complications through several pathways, including destabilizing arterial plaques and increasing clotting risk.⁶

Supportive Care Is Still the Backbone

For most adults with RSV, treatment means managing symptoms while the body clears the virus. That includes staying hydrated, using fever reducers as needed, and monitoring for worsening respiratory function. For those sick enough to be hospitalized, supplemental oxygen is often necessary, and a subset will require high-flow nasal cannula or mechanical ventilation. There is no magic bullet here, but “supportive care” is not the same as “doing nothing.” Aggressive respiratory support, early recognition of deterioration, and keeping the patient well-oxygenated all influence outcomes.

One common question is whether steroids help. They are prescribed frequently in hospitalized RSV patients, partly because many of these patients already have COPD or asthma and steroids are standard in those exacerbations. But a study specifically evaluating steroid use in hospitalized adults with RSV found no significant differences in peak viral load, duration of viral shedding, or nasal immune markers between steroid-treated and untreated patients. The steroid-treated group did show slightly weakened antibody responses to the virus.⁷ In other words, steroids did not clearly help fight the RSV infection itself, and there is a signal they might dampen the immune response you actually want. That does not mean steroids are always wrong for an RSV patient; if someone is having a genuine COPD flare triggered by the virus, steroids may still be appropriate for the exacerbation. But using them reflexively because the patient “looks inflamed” does not appear to accelerate RSV recovery.

Ribavirin for Immunocompromised Patients

The one antiviral that sees real-world use against RSV in adults is ribavirin, an older broad-spectrum drug. Its use is concentrated almost entirely among transplant recipients and other people with severely weakened immune systems, where RSV can be devastating. Originally, ribavirin was given by inhalation, a cumbersome process requiring special equipment and isolation rooms that drove costs up dramatically. Oral ribavirin has emerged as a practical alternative.

In moderately to severely immunocompromised patients, oral ribavirin (with or without intravenous immunoglobulin) was well-tolerated and showed clinical benefit.⁸ A study in lung transplant recipients found that oral ribavirin appeared effective, was well-tolerated, provided considerable cost savings, and reduced hospital stays compared to the intravenous or inhaled forms.⁹ In bone marrow transplant recipients, a direct comparison of oral versus inhaled ribavirin found no meaningful difference: both groups had the same 27 percent rate of progression to lower respiratory tract infection, and mortality rates were statistically similar at both 30 and 90 days.¹⁰

The shift toward oral ribavirin matters practically. Aerosolized ribavirin is expensive, logistically difficult, and requires healthcare workers to wear respirators during administration. Oral ribavirin simplifies everything. That said, ribavirin is not without side effects, including anemia, and the evidence supporting its use remains based on observational studies and retrospective comparisons rather than large randomized trials. For the general, healthy adult with RSV, ribavirin is not indicated. Its niche is transplant medicine and severe immunosuppression.

There is also a small case series reporting that remdesivir, originally developed for Ebola and later used widely for COVID-19, showed clinical improvement in five bone marrow transplant recipients with RSV lower respiratory tract infection.¹¹ Five patients is far too few to draw firm conclusions, but it hints at another potential option for this vulnerable group.

Antivirals in the Pipeline

The real action in RSV treatment is in clinical development, where several drugs targeting different parts of the virus are being tested. These are not available for routine use yet, but they represent what may eventually change the “there is no treatment” answer.

Presatovir is an oral RSV fusion inhibitor that has been through multiple phase 2b trials. In a human challenge study (where healthy volunteers are deliberately infected), it reduced viral load and symptoms. In naturally infected adults, including transplant recipients and hospitalized patients, drug resistance emerged in roughly 8 percent of treated patients across the combined trials. Those who developed resistant virus saw less viral load reduction during treatment but, interestingly, had similar clinical outcomes to those without resistance.¹² That is a pattern worth watching: the drug clearly has antiviral activity, but the clinical benefit in real-world patients has been harder to demonstrate conclusively.

Rilematovir, another oral antiviral, showed more encouraging early signals. In a pilot phase 2a trial among non-hospitalized adults with RSV, the higher dose shortened the time to resolution of key RSV symptoms by roughly two to three days compared to placebo, with a more pronounced effect in patients who started treatment within three days of symptom onset.¹³ That early-treatment window is a recurring theme: modeling based on human challenge studies suggests that reducing RSV viral load early in infection could have a therapeutic window similar to or even wider than what we see with influenza antivirals like oseltamivir.¹⁴

Perhaps the most striking early data comes from EDP-323, a first-in-class oral drug that works differently from fusion inhibitors by targeting the RSV L-protein. In a human viral challenge study, participants who received EDP-323 showed rapid symptom improvement within the first 24 hours. Total symptom scores dropped by about two-thirds compared to placebo, and lower respiratory tract symptoms were reduced by 85 percent or more. Viral load fell by roughly 85-87 percent.¹⁵ These are challenge-study results in otherwise healthy volunteers, so they cannot be directly extrapolated to elderly or immunocompromised patients, but the magnitude of the effect is noteworthy.

The Complications That Matter Most

Much of what makes RSV dangerous in adults is not the virus itself but what it sets in motion. Bacterial superinfection is a serious and underappreciated risk. In one study, about 9 percent of adults hospitalized with RSV pneumonia developed a bacterial superinfection, and those patients fared far worse: their hospital stays were significantly longer (16 days versus 10) and they were admitted to the ICU at three times the rate of patients with RSV alone.¹⁶ Another study found that bacterial superinfection carried a mortality rate of nearly 39 percent, compared to about 4 percent in RSV patients without it. Mechanical ventilation and systemic corticosteroid use were both independently associated with developing these secondary infections.¹⁷

That last point circles back to the steroid question. If steroids are linked to higher rates of bacterial superinfection, and superinfection is one of the deadliest complications of RSV hospitalization, the case for reflexive steroid use looks even weaker. This is a place where treatment decisions for RSV need to be more nuanced than “treat the inflammation.”

Cardiovascular complications are the other major concern. A large study found that in the first week following RSV-related hospitalization, the risk of heart attack was nearly 9 times higher than baseline, risk of stroke was about 7 times higher, risk of heart failure exacerbation was roughly 12 times higher, and risk of arrhythmia was over 16 times higher. These elevated risks tapered over subsequent weeks but remained above baseline for at least three weeks.¹⁸ RSV-related hospitalizations also triggered COPD exacerbations at dramatically elevated rates, and including heart failure and COPD flares in the tally boosted the estimated incidence of RSV-related hospitalizations in adults over 50 by 58 percent compared to counting acute respiratory illness alone.¹⁹

For practical purposes, this means that if you or a family member is hospitalized with RSV and has underlying heart disease or COPD, close cardiac monitoring in the days after admission is not overkill. The acute respiratory infection may be what gets the attention, but the cardiovascular fallout can be what causes the most harm.

Why Timing Matters for Any Future Antiviral

A consistent finding across RSV antiviral trials is that earlier treatment produces better results. The rilematovir trial showed a more pronounced effect when treatment started within three days of symptom onset. Modeling from controlled human infection studies suggests RSV has a therapeutic window comparable to influenza, where antivirals work best when given within 48 hours.¹⁴ The challenge for RSV is that most adults do not get tested for it early. They assume they have a cold or the flu, and by the time the illness worsens enough to seek medical care, the optimal treatment window may have closed.

If and when an effective RSV antiviral reaches the market, the biggest practical barrier may not be the drug itself but the testing infrastructure. Multiplex tests that check simultaneously for influenza, COVID-19, and RSV are increasingly available, and their use during respiratory illness season could change the game by catching RSV infections early enough for antivirals to work.

Prevention as the Most Effective Treatment Strategy

For now, prevention is the strongest tool adults have. Three RSV vaccines have been evaluated in older adults, and their performance is encouraging. A systematic review found that Arexvy reduced RSV-related hospitalizations in older adults by roughly 60-65 percent, Abrysvo showed 58-63 percent efficacy, and mResvia demonstrated 55-58 percent efficacy against RSV illness.²⁰ Phase III data confirmed that single-dose vaccination prevented RSV-associated lower respiratory tract disease across two RSV seasons in adults aged 60 and older.²¹

These are not the 90-plus percent efficacy numbers people became accustomed to hearing about early COVID-19 vaccines, but they are clinically meaningful. Reducing hospitalizations by 60 percent in a population where hospital stays average nearly 13 days and where cardiovascular events spike dramatically afterward is a big deal. If you are 60 or older, or if you have chronic heart or lung disease, vaccination is the single most impactful thing you can do about RSV right now.

Controlling RSV Spread in Care Facilities

Long-term care facilities are particularly vulnerable to RSV outbreaks because they house exactly the population at highest risk: older adults living in close quarters, often with multiple chronic conditions. Reports from outbreaks in these settings illustrate both the challenge and the available playbook. In one memory care unit, 20 out of 29 residents tested positive over a 21-day period. The facility implemented twice-weekly testing, enhanced cleaning, staggered mealtimes with outdoor dining, and canceled group activities and visitations. The outbreak was contained to that single unit.²²

A review of RSV outbreaks in long-term care highlighted cohorting (separating infected and uninfected residents) as one of the most effective strategies, though physical facility layout and staffing shortages can make implementation difficult in practice.²³ Another outbreak report from a VA long-term care facility emphasized that rapid PCR testing and aggressive infection control measures were the keys to halting transmission.²⁴ None of this is glamorous, but for the most vulnerable adults, preventing RSV exposure through institutional infection control is a form of treatment in itself, because once these patients are infected, options narrow quickly.

The Functional Aftermath in Older Adults

One dimension of RSV illness in adults that rarely gets discussed is what happens after the acute infection resolves. For older adults, the hospitalization itself can set off a cascade of functional decline. Bed rest leads to muscle loss, delirium during acute illness can impair cognition that does not fully bounce back, and the inflammatory storm of the infection interacts with the chronic low-grade inflammation already present in aging bodies. A review examining post-infection trajectories in adults 65 and older identified RSV alongside pneumonia, influenza, and COVID-19 as a driver of sustained functional disability through these overlapping mechanisms.²⁵ In practical terms, an older adult who was living independently before RSV hospitalization may not return to the same level of independence afterward. That makes preventing severe RSV illness and minimizing hospital days all the more urgent, and it is another argument for vaccination and early, aggressive supportive care when infection does occur.

RSV treatment in adults also carries a significant economic toll. In Germany, hospitalized patients with RSV stayed nearly twice as long as matched controls, and healthcare costs ran thousands of euros higher per admission.²⁶ In the U.S., the estimated annual hospitalization costs for RSV among adults aged 50-59 alone reached over $400 million, a population that does not yet routinely receive RSV vaccines.¹ That gap between who gets sick and who gets vaccinated is one of the clearest unmet needs in adult RSV care today.